Analyst Weighs Patent Cliff Risks Against Insmed’s (INSM) Growth Story
Insmed Inc. (NASDAQ:INSM) is among the best debt-free stocks to buy now.
Insmed Inc (INSM)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bayforest Capital Theodoros Tsagaris | 1,421 | $247,311 | 0.18% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $66.35 | 1,130 | $74,975.50 | 3,025 | 2025-05-21 | Filing | |
| $66.87 | 1,895 | $126,718.65 | 1,895 | 2025-05-20 | Filing | |
| $19.29 | 10,000 | $192,900.00 | 10,000 | 2023-05-15 | Filing | |
| $19.29 | 10,000 | $192,900.00 | 298,615 | 2023-05-15 | Filing | |
| $17.70 | 10,000 | $177,000.00 | 15,900 | 2022-11-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $160.70 | 254 | $40,817.80 | 306,891 | 2026-01-20 | Filing | |
| $159.85 | 2,229 | $356,305.65 | 307,145 | 2026-01-20 | Filing | |
| $158.99 | 5,967 | $948,693.33 | 309,374 | 2026-01-20 | Filing | |
| $158.37 | 1,243 | $196,853.91 | 315,341 | 2026-01-20 | Filing | |
| $156.80 | 1,006 | $157,740.80 | 316,584 | 2026-01-20 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 21,076,344 | $3,668,126,910 | 0.05% | |
| 2. | 1,867,635 | $325,043,194 | 0.05% | |
| 3. | 958,963 | $167,256,939 | 0.16% | |
| 4. | 562,296 | $97,862,072 | 0.06% | |
| 5. | 435,442 | $75,784,326 | 0.04% |
News See All
12 Best Debt-Free Stocks to Buy Now
The growing reliance on debt to finance multi-billion-dollar artificial intelligence and AI-infrastructure investments has come under increasing scrutiny.
Jim Cramer Commented on These 21 S&P 500 and Nasdaq-100 Stocks
Jim Cramer, the host of Mad Money, told viewers on Monday that investors should prioritize owning high-quality stocks and holding onto them, instead of constantly jumping in and out of trades where prices...
Insmed (INSM) Rose Following Drug Approval
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Here’s What Lifted Insmed Incorporated (INSM) in Q3
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Approval of Brinsupri Lifted Insmed Incorporated (INSM) in Q3
Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Insmed Incorporated (NASDAQ:INSM) Q3 2025 Earnings Call Transcript
Operator: Thank you for standing by. My name is Kayla, and I will be your conference operator today. At this time, I'd like to welcome everyone to the Insmed Third Quarter 2025 Financial Results.
Insmed (INSM) Hits All-Time High as Firm Posts Highly Optimistic Outlook
Insmed rallied for a fourth straight day to reach a new all-time high, as investors took heart from a highly optimistic business outlook for the full-year period, despite widening its net loss in the ...
Does Insmed Incorporated (INSM) Have a Promising Pipeline?
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Ohio Retirement Fund Invests in Insmed Incorporated (INSM)
Insmed Incorporated (NASDAQ:INSM) is among the most promising biotech stocks to buy according to hedge funds.
Hedge Fund Resource Center Billionaire Hedge Funds
